References
- Lowry J A, Mackay J P. GATA-1: one protein, many partners. Int J Biochem Cell Biol 2006; 38: 6–11
- Mehaffey M G, Newton A L, Gandhi M J, Crossley M, Drachman J G. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood 2001; 98: 2681–2688
- Del Vecchio G C, Giordani L, De Santis A, De Mattia D. Dyserythropoietic anemia and thrombocytopenia due to a novel mutation in GATA-1. Acta Haematol 2005; 114: 113–116
- Greene M E, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, et al. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis 2003; 31: 351–356
- Crispino J D. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr Blood Cancer 2005; 44: 40–44
- Yamaguchi Y, Zon L I, Ackerman S J, Yamamoto M, Suda T. Forced GATA-1 expression in the murine myeloid cell line M1: induction of c-Mpl expression and megakaryocytic/erythroid differentiation. Blood 1998; 91: 450–457
- Iwasaki H, Mizuno S, Wells R A, Cantor A B, Watanabe S, Akashi K. GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages. Immunity 2003; 19: 451–462
- Vannucchi A M, Bianchi L, Paoletti F, Di Giacomo V, Migliaccio G, Migliaccio A R. Impaired GATA-1 expression and myelofibrosis in an animal model. Pathol Biol (Paris) 2004; 52: 275–279
- Vannucchi A M, Pancrazzi A, Guglielmelli P, Di Lollo S, Bogani C, Baroni G, et al. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol 2005; 167: 849–858
- Wolanskyj A P, Lasho T L, Schwager S M, McClure R F, Wadleigh M, Lee S J, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–213
- Tefferi A, Lasho T L, Gilliland G. JAK2 mutations in myeloproliferative disorders. N Engl J Med 2005; 353: 1416–1417, author reply 1416–1417
- Levine R L, Wadleigh M, Cools J, Ebert B L, Wernig G, Huntly B J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397
- Tefferi A, Lasho T L, Schwager S M, Steensma D P, Mesa R A, Li C Y, et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005; 131: 320–328
- Tefferi A, Vardiman J W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22
- Baxter E J, Scott L M, Campbell P J, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061
- Patmasiriwat P, Fraizer G, Kantarjian H, Saunders G F. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia 1999; 13: 891–900
- Debili N, Coulombel L, Croisille L, Katz A, Guichard J, Breton-Gorius J, et al. Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood 1996; 88: 1284–1296